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Cognitive remission: a novel objective for
the treatment of major depression?
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Michael Berk4,7 and André F. Carvalho3*
Abstract
Background: Cognitive dysfunction in major depressive disorder (MDD) encompasses several domains, including
but not limited to executive function, verbal memory, and attention. Furthermore, cognitive dysfunction is a
frequent residual manifestation in depression and may persist during the remitted phase. Cognitive deficits may
also impede functional recovery, including workforce performance, in patients with MDD. The overarching aims of
this opinion article are to critically evaluate the effects of available antidepressants as well as novel therapeutic
targets on neurocognitive dysfunction in MDD.
Discussion: Conventional antidepressant drugs mitigate cognitive dysfunction in some people with MDD.
However, a significant proportion of MDD patients continue to experience significant cognitive impairment.
Two multicenter randomized controlled trials (RCTs) reported that vortioxetine, a multimodal antidepressant,
has significant precognitive effects in MDD unrelated to mood improvement. Lisdexamfetamine dimesylate was
shown to alleviate executive dysfunction in an RCT of adults after full or partial remission of MDD. Preliminary
evidence also indicates that erythropoietin may alleviate cognitive dysfunction in MDD. Several other novel agents
may be repurposed as cognitive enhancers for MDD treatment, including minocycline, insulin, antidiabetic agents,
angiotensin-converting enzyme inhibitors, S-adenosyl methionine, acetyl-L-carnitine, alpha lipoic acid, omega-3 fatty
acids, melatonin, modafinil, galantamine, scopolamine, N-acetylcysteine, curcumin, statins, and coenzyme Q10.
Summary: The management of cognitive dysfunction remains an unmet need in the treatment of MDD. However,
it is hoped that the development of novel therapeutic targets will contribute to ‘cognitive remission’, which may
aid functional recovery in MDD.
Keywords: Antidepressants, Cognition, Cognitive enhancers, Erythropoietin, Lisdexamfetamine dimesylate, Major
depression, Novel targets, Vortioxetine, Psychiatry
Background
Major depressive disorder (MDD) is a prevalent and dis-
abling condition with a high frequency of non-recovery
and recurrence, leading to substantial mortality and
morbidity [1–3]. Only a subset of individuals with MDD
(30–40 %) reach symptomatic remission after adequate
treatment with a first-line antidepressant, and many pa-
tients do not reach premorbid levels of psychosocial
functioning, such that a significant proportion of pa-
tients present residual symptoms. Cognitive symptoms
are acknowledged clinical manifestations of MDD, with
fatigue, sleepiness, and executive dysfunction being
among the most frequently reported residual manifesta-
tions of MDD [4]. The ICD-10 and DSM-5 diagnostic
criteria consider items such as ‘reduced concentration
and attention’ and ‘diminished ability to think or con-
centrate’, respectively, in relation to MDD.
On average, the standardized effect size of cognitive
impairment in a first major depressive episode (MDE)
compared to that in healthy controls is approximately
0.3. Accordingly, a meta-analysis of 13 studies in 644
symptomatic patients with first-episode depression ver-
sus 570 healthy controls showed significant impairments
in psychomotor speed, attention, and most aspects of
executive function (i.e. attentional switching, verbal
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fluency, cognitive flexibility), with small to moderate
effect sizes [5]. However, a subpopulation of MDD pa-
tients (approximately 20 %) exhibited deficits of two
standard deviations below the mean on two or more
cognitive domains [6]. Notwithstanding the heterogeneity
across individual studies, the most replicated findings in-
dicate that cognitive impairment in MDD encompasses
several domains, notably attention, memory, psychomotor
speed, and executive function [7–9]. Impairments in ex-
ecutive function and attention may persist after the
affective symptoms are fully mitigated [10]. In addition, a
significant proportion of patients with MDD do not re-
cover baseline levels of psychosocial functioning even
when they meet the conventional definition of remission
(e.g. a score ≤7 on the Hamilton Depression Rating Scale
(HDRS)) [2, 11, 12], suggesting that non-affective dimen-
sions and domains are critical determinants of functional
outcome. This finding is particularly important when con-
sidering that impairments in psychosocial functioning,
notably decrements in work productivity, are key determi-
nants of MDD-related societal costs [13]. Several lines of
evidence suggest that cognitive dysfunction is an import-
ant mediator of functioning, including workforce perform-
ance, in MDD [14–16].
Despite standard antidepressants, many individuals con-
tinue to complain of and/or manifest cognitive deficits con-
tributing to a diminished quality of life and functional
outcome [17–20]. Furthermore, some pilot studies show
that cognitive deficits in MDD patients may predict non-
response to treatment with selective serotonin reuptake in-
hibitors (SSRIs) or dual serotonergic-noradrenergic reuptake
inhibitors (SNRIs), indicating that poor performance in se-
lected cognitive domains may define a patient subgroup that
requires complex or additional treatment [21–23].
The aim of this opinion article is to summarize evidence
of possible procognitive effects of standard antidepressant
agents and to describe novel therapeutic targets for the
management of neurocognitive impairment in MDD. We
briefly review relevant clinical aspects pertaining to the as-
sessment and effect of cognitive impairment in adults with
MDD since we have critically evaluated these in a previous
article [24].
Discussion
A significant body of evidence shows that individuals
with MDD exhibit clinically significant cognitive impair-
ment across multiple domains. The most frequent find-
ings include small to moderate deficits in attention [22],
working memory [25], learning [10], processing speed
[26], and executive functions [27].
Methodological challenges in the study of cognition in MDD
Insight into the nature, course, and implications of
cognitive dysfunction in MDD has been limited by
heterogeneous demographic features (e.g. age and educa-
tional attainment), clinical compositions (e.g. first,
multi-episode or chronic depression, severity of symp-
toms, depression subtypes, age of onset, substance use,
and comorbid medical conditions), and treatment as-
signments. Altogether, these variables likely play a major
role in producing the inconclusive findings reported in
available studies [28]. In addition, the lack of gold-
standard tools to assess cognition in MDD and the var-
iety of neuropsychological tests employed in different
investigations hinder clear comparisons between studies.
Moreover, proper adjustment for confounding factors
(e.g. depression severity or practice effects) is frequently
lacking, which further complicates the analysis of avail-
able evidence [29]. A further limitation of these ap-
proaches for evaluating cognitive dysfunction is their
comparison with healthy, age-matched control groups.
Cognitive dysfunction on neuropsychological tests may
thus not be detectable in patients with supra-normal
premorbid function, despite their cognitive decline after
onset of illness (which may be evident in their subjective
cognitive function). Nevertheless, these patients could
still be significantly disabled because of the functional
impact of their cognitive decline in work settings [30],
particularly if their job involves complex planning and
fast decision making. Therefore, evaluation of objective
neuropsychological function should ideally be accom-
panied by an assessment of subjective cognitive function.
Notably, however, subjective and objective neuro-
psychological measures of cognition are not closely re-
lated [31, 32], indicating that patients with the greatest
objective cognitive dysfunction do not necessarily ex-
perience the most pronounced cognitive problems, and
vice versa. This finding highlights a role of other factors
(e.g. depressive symptoms) in the poor correlation between
objective and subjective cognition measures [31, 32]. In-
deed, there are several important methodological challenges
in the study of cognition in MDD that must be addressed
in future studies.
Meta-analytic evidence for non-specific cognitive
dysfunction
Notwithstanding these limitations, separate meta-analyses
provide compelling evidence that (objective) cognitive im-
pairment is a consistent, replicable, non-specific, and clin-
ically significant feature of MDD – and, for that matter,
many major psychiatric disorders [10, 14, 33–35]. For in-
stance, a meta-analysis of 24 studies in which all partici-
pants had been assessed with the same comprehensive
neuropsychological battery (Cambridge Neuropsycho-
logical Test Automated Battery) showed significant im-
pairments in executive functions, attention, and memory
in the symptomatic phases of MDD (Cohen’s d effect sizes
ranging from −0.34 to −0.65) [10]. In keeping with the
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view that broad-based cognitive deficits are associated
with MDD, the presence of significant deficits in ex-
ecutive functions and psychomotor speed in adults
with MDD has been confirmed by a separate meta-
analysis of 113 studies (Cohen’s d effect sizes ranging
from −0.32 to −0.97) [34].
Course of cognitive dysfunction in MDD
Cognitive dysfunction in depression does not appear to
be simply an epiphenomenon of mood symptoms (e.g.
fatigue) but instead is a core and persisting phenomenon
[36]. For example, a systematic review of 11 studies in-
volving 500 adult patients in remission from MDD doc-
umented persistent deficits in sustained and selective
attention, memory, and executive function. However, the
heterogeneity across studies did not allow for the esti-
mation of precise effect sizes [37]. In a subsequent study
of individuals with unipolar depressive disorder in
remission, Hasselbalch et al. [38] reported that the se-
verity of cognitive impairment increases as a function
of the cumulative duration of MDEs and, additionally,
indicated that the occurrence of psychotic features is
associated with worse cognitive performance. Finally, a
meta-analysis of 27 studies investigating euthymic adult
subjects with MDD showed that executive dysfunction
(namely lower inhibitory control) could persist after
improvement of depressive symptoms [39]. Moreover,
these analyses noted an effect of age as a correlate of
poor cognitive performance in MDD, introducing dis-
parate etiopathogenic mechanisms (e.g. vascular and
neurodegenerative factors).
Notwithstanding the correlation between episode fre-
quency and deficits in cognitive performance, clinically
significant deficits in cognitive function have been re-
ported among adults with MDD experiencing an index
depressive episode. For example, a meta-analysis of 13
studies on adults with a first MDE reported significant
impairment in psychomotor speed (effect size 0.48), at-
tention (effect size 0.36), and visual learning and mem-
ory (effect size 0.53) compared with healthy controls [5].
In addition, a recent meta-analysis of 17 studies compar-
ing 447 children and adolescents with MDD with 1,347
healthy controls indicated significant deficits in inhibi-
tory control, phonemic verbal fluency performance, ver-
bal memory, sustained attention, and planning ability, as
well as in working memory and shifting ability (random
effects standardized mean difference ranging from 0.21
to 0.77) among MDD patients [40].
Furthermore, preliminary evidence suggests that cogni-
tive impairment may even pre-date the onset of clinically
significant depressive symptoms. Different population-
based studies have suggested that poor performance in
tests of episodic memory may predict the onset of depres-
sive symptoms [26, 41]. Moreover, the large-scale Vietnam
Era Twin Study showed that, after adjustment for con-
founders, a lower score on a general cognitive measure
was associated with increased risk of developing de-
pressive symptoms [42]. Finally, this assumption was
further supported by the findings of a Danish study of
high-risk twins [43].
Taken together, using the classification proposed by
Davis et al. [44], these studies suggest that cognitive im-
pairment may represent a risk biomarker that may even
antedate illness onset, a trait marker present in remitted
patients, a marker of progression showing greater sever-
ity with illness progression, and a state or acuity marker
of MDD, with more marked effects on acutely ill individ-
uals. In addition, cognitive impairment is a principal
determinant of quality of life and function. Thus, it
could be postulated that aspects of cognitive dysfunc-
tion in MDD may reflect a variety of divergent pro-
cesses in this illness.
Clinical implications of cognitive dysfunction in MDD
Current evidence supports a putative mediational role of
cognitive dysfunction in psychosocial functioning, not-
ably workforce productivity [45, 46]. Importantly, it has
been suggested that workplace impairment may con-
tribute to more than 60 % of the MDD-related eco-
nomic burden [47].
Data from The European Study of the Epidemiology of
Mental Disorders, a cross-sectional survey including
21,425 adults from six European countries, reported that
cognitive deficits and embarrassment (i.e. stigma) account
for half of the association between a MDE and work loss
[15]. Consistent with these data, results from a study in-
volving fully employed adults with MDD documented a
significant interference of subjective cognitive deficits with
workplace role-functioning, regardless of antidepressant
therapy [48]. In this same vein, Jaeger et al. [16] measured
the neurocognitive performance of patients following
hospitalization for an MDE and documented that more
pronounced neurocognitive deficits at 6 months follow-up
were associated with poorer functional outcome and
greater disability. A recent systematic review further sug-
gests a putative mediational role of neurocognitive impair-
ment in functioning, including workforce performance,
among individuals with MDD [30].
In recent decades, the target clinical endpoints for
MDD treatment have evolved from response (i.e. a 50 %
reduction in severity of depressive symptoms from base-
line) to the objective of clinical remission [49]. In research
settings, the definition of remission is based on the
achievement of specific cut-off scores on rating scales of
depressive symptom severity (e.g. 17-item HDRS score ≤7;
Montgomery-Asberg Depression Rating Scale (MADRS)
score ≤10) [50, 51]. However, the concept of remission
provides only a vague theoretical definition that may be
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influenced by the psychometric limitations of available in-
struments [52, 53]. Even a score of 7 on the HDRS, for ex-
ample, may not reflect true remission [54], and it has been
suggested that lower scores (<5) correlate with objective
cutoff points. Furthermore, remission does not equate to
recovery. In fact, the acknowledgement that even sub-
threshold depressive symptoms may be associated with
substantial psychosocial impairment has led some experts
to postulate that functional recovery is likely to represent
the proper target for MDD treatment [2]. Improvements
in quality of life are important for long-term social func-
tioning and have been increasingly considered targets for
MDD treatment. However, quality of life measures are sig-
nificantly influenced by age, depressive symptom severity,
and episode recurrence, as well as chronic somatic or
painful comorbidities and treatment status (e.g. number of
medications or antidepressant switch) [55, 56]. Since cog-
nitive dysfunction is one of the residual symptoms of
MDD that most strongly impairs quality of life and since
accumulating evidence suggests that persistent cognitive
impairment prevents full recovery even following the reso-
lution of depressive episodes, some authors have advo-
cated for the achievement of ‘cognitive remission’ as an
appropriate, novel aim for MDD treatment [57, 58].
Cognitive effects of conventional antidepressants
Direct or indirect effects on cognition?
A number of clinical studies have primarily evaluated
the effect of conventional antidepressants on cognitive
performance in individuals with MDD, although most of
these studies have not evaluated cognitive function as a
primary outcome. In addition, the lack of a placebo con-
trol and proper statistical control for the effects of clin-
ical severity (i.e. through path analysis) may contribute
to inconsistencies across findings. Nevertheless, conven-
tional antidepressants are generally associated with a
beneficial effect on cognitive impairment in individuals
with MDD, which may be mediated at least in part by
improvement in affective symptoms. For example, it was
reported that SSRI treatment led to a significant im-
provement in memory performance (i.e. immediate and
delayed verbal, immediate visual, and declarative mem-
ory) in individuals with MDD [59, 60]. Moreover, two
studies showed that treatment with sertraline is associated
with significant improvements in psychomotor speed and
executive functions [61, 62]. On the other hand, other
findings indicated that sertraline, citalopram, or paroxe-
tine administration, were not associated with significant
changes in cognitive performance in a cohort of elderly
patients with major depression, whereas a beneficial
effect was observed in patients with minor depression,
regardless of changes in the severity of depressive
symptoms and concomitant benzodiazepine or psycho-
tropic drug use [63].
In a recent 8-week, double-blind, comparative random-
ized controlled trial (RCT) of SSRIs (escitalopram) and
bupropion on adults with MDD (n = 36), both treatments
were significantly associated with improved immediate as
well as delayed verbal and non-verbal memory, global
function, and measures of work productivity [64]. More-
over, no significant between-group differences were ob-
served in this study, in contrast to data obtained from a
cross-sectional naturalistic study that reported a superior
effect of bupropion over SSRIs or venlafaxine on cognitive
function [65]. However, whereas in this study the SSRI
group (n = 27) performed significantly worse than healthy
controls in tests of psychomotor and processing speed
and cognitive flexibility, and the venlafaxine group per-
formed worse than controls in measures of processing
speed, the bupropion group (n = 27) did not differ from
healthy controls in any cognitive measure; this aspect
limits the generalizability of these findings.
The beneficial effects of mirtazapine on cognition after
3 months of treatment were reported in a study of indi-
viduals in an acute MDE [66]. Importantly, improve-
ments in cognitive performance were not correlated
with the degree of amelioration of depressive symptoms,
suggesting that they were not entirely accounted for by
the resolution of the MDE. Finally, tianepine treatment
for 3 months significantly improved cognitive functions
(i.e. short-term memory and learning, as well as reaction
time and attention) in patients with mild and moderate
MDD [67]. These designs are, however, unable to disen-
tangle indirect effects related to the resolution of depres-
sive symptoms from direct pro-cognitive effects.
Interventions that target multiple neurochemical sys-
tems simultaneously (e.g. SNRIs) might be more likely to
improve cognitive performance than treatments target-
ing only a single system (e.g. SSRIs) [68]. For instance, a
trial including adults with MDD treated with escitalo-
pram (SSRI; n = 36) or duloxetine (SNRI; n = 37) for 24
weeks showed that SNRIs were superior to SSRIs in
ameliorating memory performance [19]. Despite both
escitalopram and duloxetine improving measures of
working memory, attention, executive function, mental
processing and speed, and motor performance, the im-
provement induced by duloxetine was greater than that
induced by escitalopram in episodic and working memory.
A caveat, however, is the assessment of cognition as a sec-
ondary outcome [19]. Nevertheless, another double-blind
RCT investigated the effect of duloxetine treatment on
cognition deficits in elderly subjects with recurrent de-
pressive episodes as a primary outcome [69]. Duloxetine
treatment for 8 weeks was associated with an increase in a
composite cognitive index relative to that measured for a
placebo group. This global improvement was indexed by
increases in measures of verbal learning and recall, along
with greater decreases in depression severity (assessed by
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HDRS and the Geriatric Depression Scale). Changes in
the cognitive composite index were partially inde-
pendent of improvements in overall depression sever-
ity. More recently, the cognitive-enhancing effects of
duloxetine have been further supported by a 12-week
study including adults presenting MDD with baseline
cognitive deficits (n = 30) [70]. Path analysis showed
that better cognitive performance was determined not
only by decreases in depression severity but also by
enhancements of verbal learning and memory per-
formance. However, inconsistent with these findings,
duloxetine did not differ from a placebo in several
assessed cognitive domains in a recent study on eld-
erly individuals with MDD [71].
A recent meta-analysis further indicates that standard
antidepressant drugs may ameliorate certain cognitive
domains in patients with MDD, namely psychomotor
speed and delayed recall [20]. However, the evidence
base remains limited, and the effect sizes derived from
this meta-analysis were small in magnitude (standard
mean difference was 0.16 for psychomotor speed and
0.24 for delayed recall, respectively). In addition, drawing
firm conclusions on the comparability of procognitive
effects of antidepressants with distinct mechanisms of
action requires further well-designed studies. Evidence
of direct procognitive effects of antidepressants is pro-
vided by studies in which cognitive dysfunction is speci-
fied as a primary outcome of interest, along with the
inclusion of a placebo group and appropriate statistical
approaches, such as path analysis, to parse direct effects
from more pseudo-specific effects such as cognitive
changes secondary to mood improvement. Similarly, a
recent systematic review indicates that although aug-
mentation therapy may potentially improve cognitive
performance after remission of a MDE, available evi-
dence should be interpreted cautiously because of sig-
nificant heterogeneity in study design and treatment
duration across studies [72].
Cognition as a predictor of antidepressant efficacy
Few studies have investigated whether neuropsycho-
logical measures predict response to treatment with an-
tidepressants. For instance, a small study that enrolled
adults with MDD (n = 20) evaluated the effects of 8
weeks of bupropion treatment (150 mg/day) on cogni-
tive performance and reported that lower pretreatment
performance on visual memory and processing speed
tasks predicts better treatment response [23], supporting
the hypothesis that depressed patients with psychomotor
slowing may show greater response to bupropion. Con-
versely, a neurocognitive profile characterized by psy-
chomotor slowing may aid in the identification of a
subgroup of patients with MDD who are less likely to re-
spond to SSRI monotherapy [73]. For instance, a study
on 70 adult individuals with MDD and 57 healthy con-
trols assessed the value of certain neurocognitive tests of
executive functions and psychomotor speed as differen-
tial predictors of response to SSRIs (escitalopram or cita-
lopram), dual therapy, or bupropion [74]. Whereas poor
pretreatment word fluency performance predicted non-
response to SSRIs and longer choice reaction time on
the Stroop Test predicted non-response to SSRIs or dual
therapy, patients who responded to bupropion tended to
show the opposite pattern of neurocognitive perform-
ance, exhibiting slower reaction time and poorer pre-
treatment word fluency performance compared with
those of controls. Thus, the authors posit that certain
neurocognitive tests, mostly those that depend on psy-
chomotor speed, may serve as differential predictors of
clinical response to an SSRI or to an SNRI as opposed to
bupropion.
In adults with late-life MDD (n = 177), greater pretreat-
ment verbal memory was associated with better treatment
response [75]. Conversely, in elderly subjects (age >65
years; n = 58) with MDD, executive dysfunction was asso-
ciated with increased risk of relapse after 16-week therapy
with nortriptyline, as well as higher recurrence rates after
a 2-year placebo-controlled maintenance phase [76]. Sub-
jects with late-onset depression (i.e. >60 years old) are
likely to experience increased impairment in verbal mem-
ory, processing speed, and executive function with respect
to depressed adults [39]. In particular, executive deficits in
the elderly were found to correlate with increased residual
symptomatology, higher recurrence rates, and worse re-
sponse to antidepressant medication [77, 78]. However, a
meta-analysis of 17 studies of late-life MDD indicated that
better performance on tests of executive function (i.e. De-
mentia Rating Scale initiation and perseveration subtest)
and non-executive function (including two tests of psy-
chomotor speed, one test of construction, and one test of
memory) is associated with response to antidepressant
treatment [79]. Thus, the authors concluded that specific
cognitive deficits per se do not offer a reliable basis for
making clinical judgments about probable illness course,
in contrast to the depression-executive dysfunction model,
according to which the occurrence of executive dysfunc-
tion portends poor response to antidepressant medication.
The confounding effect of age
The major caveat of studies showing the efficacy of anti-
depressant therapy in treating cognitive deficits is the
over-representation of elderly subjects (age >65 years) in
the samples, which limits their external validity. Indeed,
the effects of antidepressants on cognitive performance
in the elderly are likely negatively influenced by the
combined effects of comorbidities and a greater likeli-
hood of side effects. Notwithstanding the paucity of data
showing beneficial effects of antidepressants on cognitive
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performance in non-elderly adult subjects with MDD,
converging evidence supports the assumption that the
clinical magnitude of antidepressant effects is also small in
this population. A systematic review showed that different
antidepressant treatments induced smaller changes in
measures of executive function and attention, despite clin-
ically perceived changes in verbal learning, memory, ver-
bal fluency, and psychomotor speed. Thus, these factors
might represent trait-like markers of MDD [72].
Cognitive side effects of antidepressant medication
Long-term therapy with certain antidepressants may also
be linked to cognitive side effects in adult subjects with
MDD. For instance, treatment with antidepressants has
been associated with increased cognitive deficits, such as
apathy, inattentiveness, forgetfulness, word-finding diffi-
culty, and mental slowing, in depressed individuals
reaching partial or full remission (n = 117) [80]. Signifi-
cant impairment of executive functioning (i.e. phonemic
fluency) has also been reported following treatment with
SSRIs [60]. Accordingly, another cross-sectional study
that investigated the effects of different antidepressants
on cognitive performance suggested that class-specific
side effects may account, at least in part, for the long-
lasting cognitive deficits observed in subjects with MDD
in remission [81]. The study used the Wechsler Memory
Scale-Revised and the Stroop Color and Word Test to
assess memory and executive function in depressed sub-
jects treated with tricyclic antidepressants (TCA; n = 29),
SSRIs/SNRIs (n = 21), or medication free (n = 19), as well
as healthy controls (n = 31). Individuals from both anti-
depressant groups, but not from the medication-free
group, showed poorer performance in visual memory
with respect to healthy controls. Regarding executive
function, only subjects in the TCA group showed worse
performance than the controls. This deleterious effect
might be explained at least in part by the anticholinergic
effects of some TCAs [82]. Despite evidence of cognitive
impairment in medication-free individuals with MDD
[83], different domains of global cognition might be
negatively affected by class-specific antidepressant side
effects. The pathways whereby this effect occurs are
opaque; changes in appetite and energy balance may
have negative effects on cognition because interference
in the metabolism of glucose may lead to insulin resist-
ance [84], abnormal neurotransmitter turnover, mito-
chondrial dysfunction, and energy deficits, as well as
changes in neural plasticity [85]. Finally, psychotropic
agents may have a similar effect on the immune system
and, consequently, on cognitive performance [86, 87].
Cognitive dysfunction as a target for novel treatments
Despite the recent discovery of compounds with potential
therapeutic use in MDD-related cognitive dysfunction,
there are still few choices available. However, some com-
pounds under preliminary investigation show promising
results with respect to their procognitive potential. There
is also great research interest in the development or repur-
posing of various agents as cognitive enhancers for MDD.
Herein, we discuss putative treatment options to conven-
tional treatments that deserve future research consider-
ation (Table 1).
Vortioxetine
Vortioxetine (Lu AA21004) is an antidepressant that acts
as an antagonist of the 5-HT3 and 5-HT7 serotonin re-
ceptors, partial agonist of the 5-HT1B serotonin receptor,
agonist of the 5-HT1A receptor, and inhibits the sero-
tonin transporter [88]. Preclinical studies have shown
that vortioxetine may influence learning and memory
processes by improving hippocampal synaptic plasticity
and increasing the output of pyramidal cells [89]. Fur-
thermore, it has been postulated that vortioxetine may
improve the cognitive symptoms of MDD through its ef-
fects on cognate serotoninergic receptors, which may
modulate glutamatergic neurotransmission [90].
Procognitive effects were suggested by a preliminary RCT
that investigated vortioxetine treatment in non-demented
subjects with recurrent MDD (n = 453) [71]. Although
these were secondary outcome measures, vortioxetine-
treated individuals showed increased learning and memory
performance (assessed by the Rey Auditory Verbal Learning
Test; RAVLT) and higher processing speed (assessed by the
Digit Symbol Substitution Test; DSST) compared with a
placebo group, and the effects were independent of the re-
duction in depression severity (assessed by HDRS). Further-
more, a large double-blind 8-week-long RCT investigated
the effects of vortioxetine (10 mg or 20 mg) on cognitive
performance as the primary outcome measure in adults
with recurrent, moderate-to-severe MDD [91]. The study
showed that vortioxetine significantly increased a compos-
ite index calculated from the DSST and the RAVLT scores,
as well as self-reported cognitive tests (i.e. Perceived Defi-
cits Questionnaire). Path analyses showed that this effect
was largely attributable to a direct effect of treatment on
cognition because one-half to two-thirds of the procogni-
tive effect could not be the result of the overall reduction in
depression symptoms.
In accord with these findings, vortioxetine procognitive
effects were confirmed as a primary outcome in another
8-week duloxetine-referenced RCT in individuals with
moderate-to-severe MDE who reported subjective cogni-
tive dysfunction (n = 602). Significant improvements in
objective and subjective measures of cognitive function
(i.e. Number of Correct Symbols in the DSST and the at-
tention/concentration or planning/organization subscores
of the Perceived Deficits Questionnaire) were observed at
the endpoint in the group treated with vortioxetine
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compared with those of a placebo group, whereas duloxe-
tine was superior to the placebo only with respect to the
subjective measures of cognitive function. Both vortioxetine
and duloxetine were significantly superior to the placebo in
reducing depressive symptoms assessed by MADRS. Path
analysis showed that, although more than one-half of the
duloxetine effect on cognitive deficits was attributable to
improvements in depressive symptoms, the effect of vor-
tioxetine on cognitive performance was largely independent
of the alleviation of depressive symptoms [92].
Lisdexamfetamine dimesylate
Lisdexamfetamine dimesylate (LDX) is a pharmacologic-
ally inactive pro-drug of D-amphetamine approved for
Attention Deficit Hyperactivity Disorder treatment. In a
proof-of-concept RCT on MDD patients exhibiting re-
sidual symptoms after treatment with the SSRI escitalo-
pram, add-on LDX administration was effective in
reducing depressive symptoms (assessed by MADRS)
[93]. The procognitive effects of LDX in MDD were sug-
gested by an RCT that investigated LDX effects on
Table 1 Potential therapeutic targets for the treatment of cognitive dysfunction in major depressive disorder (MDD)
Agent Putative mechanisms of action Clinical evidence [Ref. No.]
Vortioxetine 5-HT3/5HT7 receptor antagonist; partial agonist
at the 5-HT1B receptor; agonist at 5-HT1A
receptor; inhibitor of the 5-HT transporter
Two multicenter RCTs having cognitive performance as the
primary outcome measure were conducted in participants
with MDD [91, 92]. Overall, vortioxetine displayed a significant
procognitive effect over several domains, which was largely
independent of the amelioration of affective symptoms.
However, a recent meta-analysis found that the overall effect
size was small (0.34) [20].
Lisdexamfetamine dimesylate D-amphetamine prodrug; enhances the efflux
of dopamine and norepinephrine in the CNS
A RCT found LDX augmentation to be efficacious in
reducing self-reported executive dysfunction among
participants with MDD (N = 143) with residual depressive
symptoms [94].
Erythropoietin Readily crosses the BBB and increases the
production of BDNF
EPO improved verbal learning and memory in a preliminary
RCT involving participants with treatment-resistant MDD
(N = 40) [97]. This effect was largely mood-independent.
However, cognitive performance was not the primary
outcome measure in this trial.
Minocycline Promotes hippocampal neurogenesis; Anti-
apoptotic effects; Anti-inflammatory activity;
Antioxidant; Modulates glutamatergic
transmission; Stabilizes the microglia
No clinical trial has investigated the potential procognitive
effects of minocycline in samples with MDD.
Thiazolidinediones Antagonist of PPAR-gamma; increased the
production of BDNF; has anti-inflammatory
and antioxidant activities
No published clinical trial has investigated the effects of
thiazolidinediones upon cognition in samples with MDD.
S-adenosyl methionine Major methyl-donor; essential for the synthesis
of several neurotransmitters; involved in the
synthesis of glutathione
A post-hoc analysis of a preliminary RCT involving 40 SSRI-
resistant participants with MDD found SAMe to improve in
self-rated recall and word-finding difficulties compared to
placebo [127].
Omega-3 PUFAs Anti-inflammatory and antioxidant activities;
Increases the production of BDNF; diminishes
microglia-related neuro-inflammation
No published clinical trials to date have investigated the
effects of omega-3 PUFAs on cognitive performance in
samples with MDD.
Modafinil Pleotropic agent that targets several
neurotransmitter systems (e.g., 5-HT, GABA,
glutamate, orexin, and histamine).
A small open-label trial has found that modafinil
augmentation improved executive function in a sample
with MDD [147].
Galantamine Rapidly reversible acetylcholinesterase inhibitor
and a potent modulator of the nicotinic
receptor; affects monoamines, GABA and
glutamate neurotransmitter systems.
Two preliminary RCTs have found no evidence for a
procognitive effect of galantamine augmentation in
participants with MDD [150, 151].
Scopolamine Potent muscarinic antagonist; modulates 5-HT,
neuropeptide Y, dopaminergic, and glutamatergic
systems.
A proof-of-concept RCT did not observe significant effects
of scopolamine in a task measuring sustained attention in
a sample with MDD [154].
N-acetylcysteine Pleotropic agent that modulates glutamate
transmission; antioxidant; anti-inflammatory effect;
anti-apoptotic activity; increases glutathione.
No published trial has investigated the effects of NAC on
cognitive function in samples with MDD.
Statins Increases BDNF; antioxidant; anti-inflammatory;
inhibits the enzyme IDO; modulates the microglia.
No published trial has investigated potential procognitive
effects of statins in samples with MDD.
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cognitive performance in adult subjects with mild MDD
(n = 143) and long-lasting executive impairment as
assessed by the Behavior Rating Inventory of Executive
Function – Adult Version self-report global executive
composite T score. LDX (20–70 mg/day) used as aug-
mentation therapy improved the executive deficits from
baseline to endpoint with respect to the placebo group
[94]. However, one limitation of this study was the use
of a self-report questionnaire to assess executive func-
tion since subjective ratings of cognitive deficits do not
necessarily correlate with objective impairments [95].
Another RCT with the primary objective of evaluating
the effect of adjunctive LDX (20–50 mg/day) on residual
symptoms and cognitive impairment in adults partially
responsive to SSRIs or SNRIs is currently under way
(ClinicalTrials.gov Identifier: NCT01148979).
Erythropoietin
Erythropoietin (EPO) is a glycoprotein primarily synthe-
sized by the kidney that acts as a hormone in the regula-
tion of erythropoiesis. EPO crosses the blood–brain
barrier and exerts antidepressant-like and neuroprotec-
tive effects enhancing hippocampus-dependent memory
and neuroplasticity, partly via increased production of
brain-derived neurotrophic factor (BDNF) [95]. In
healthy volunteers, EPO modulated neuronal activity in
a frontoparietal network during working memory and
improved executive function (i.e. verbal fluency) 1 week
after a single high-dose administration (40,000 IU) [96].
Clinical evidence of EPO procognitive potential has
been provided by an RCT involving moderately depressed
individuals (n = 40) with treatment-resistant MDD [97].
Although EPO did not show effects distinct from those of
a placebo on the primary outcome measure (i.e. HDRS
scores), it produced long-term mood-independent im-
provement in verbal learning and memory on the RAVLT.
Notably, these effects were accompanied by (and corre-
lated with) reversal of subfield hippocampal volume loss
[98]. Taken together, these findings suggest that EPO
may have cognitive-enhancing effects in MDD. How-
ever, these preliminary findings require replication in a
large-scale RCT.
Minocycline
Minocycline is a broad-spectrum tetracycline antibiotic
commonly used to treat acne, infections of the respiratory
trait, and mild rheumatoid arthritis. Minocycline is the
most lipid-soluble among tetracycline antibiotics and
shows the greatest penetration into the cerebrospinal fluid
and the central nervous system. Minocycline promotes
hippocampal neurogenesis and exerts anti-apoptotic and
anti-inflammatory activities, reducing the expression of
pro-inflammatory cytokines (e.g. IL-1β, IL-6, IL-2, TNF-α,
INF-γ) and up-regulating anti-inflammatory cytokines
(e.g. IL-10) [99]. Moreover, it exerts antioxidant properties
by suppressing free radical generation and attenuates in-
creases in lipid peroxidation [100], modulates glutamate
transmission reducing glutamate release and excitotoxi-
city, and may indirectly target the monoaminergic system
[101]. All these processes have been posited to play a role
in the neuroprogressive nature of MDD, and there is evi-
dence that pro-inflammatory status may also correlate
with poor neurocognitive performance [102].
Preclinical evidence suggests that minocycline may re-
duce cognitive impairment [103, 104]. However, clinical
trials have produced conflicting results. Two separate
RCTs on HIV-1-infected individuals with progressive
neurocognitive decline reported that treatment with ad-
junctive minocycline for 24 weeks was not associated
with significant improvements in cognitive performance
[105, 106]. Nevertheless, add-on administration of mino-
cycline for 22 weeks was associated with improvements
in executive functions in individuals with early-phase
schizophrenia [107]. Preliminary findings from an open-
label study confirmed minocycline antidepressant poten-
tial in individuals with unipolar psychotic depression
[108]. Further and larger RCT studies investigating min-
ocycline efficacy on depressive symptoms and cognitive
dysfunction are warranted.
Insulin and antidiabetic agents
Comorbid metabolic disturbances aggravate the burden of
depressive illness, in part by sharing common risk factors
and pathophysiological pathways, since impaired insulin
signaling and insulin resistance have been documented to
play an important role in the pathogenesis of MDD [109].
The localization of insulin receptors in the hippocampus
and medial temporal cortex suggests that insulin and glu-
cose homeostasis play a role in physiological memory
functions through their effect on synaptic plasticity and
cellular survival [110]. Insulin exerts anti-apoptotic activ-
ities and facilitates neuronal growth and differentiation by
promoting synapse formation, thus influencing learning
and memory processes. In addition, insulin serves as a
neuromodulator by enhancing serotonin synthesis and
inhibiting the reuptake of norepinephrine by pre-synaptic
neurons. Alterations in insulin signaling are associated
with mitochondrial dysfunction and lead to the activa-
tion of pro-inflammatory pathways, as well as increased
oxidative/nitrosative stress and glutamate excitotoxicity,
which result in neuroinflammation and neurodegenera-
tion [111]. Insulin resistance and adiposity have been
associated with poor cognitive performance on tasks of
attention, memory, and processing speed even in non-
diabetic population-based samples of middle-aged indi-
viduals [112]. Results obtained from preclinical studies
and controlled trials on healthy volunteers and individ-
uals with mild cognitive impairment or Alzheimer’s
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disease have supported the potential of intranasal insulin in
improving memory performance [113]. An RCT among
euthymic patients with bipolar disorder documented that
individuals treated with intranasal insulin exhibited signifi-
cant improvements in one measure of executive function
(in the absence of improvement across other cognitive do-
mains) compared with a placebo group [114]. An interven-
tional RCT evaluating the putative antidepressant and
procognitive effect of intranasal insulin in MDD is currently
under way (ClinicalTrials.gov Identifier: NCT00570050).
In keeping with the view outlined above, enhanced in-
sulin signaling with antidiabetic treatments, for example,
thiazolidinediones such as rosiglitazone and pioglitazone,
may preserve and/or augment cognitive function at least
in a subset of MDD patients exhibiting comorbid meta-
bolic conditions [115]. Thiazolidinediones act as agonists
of peroxisome proliferator-activated receptor gamma
and have been demonstrated to exert neuroprotective
effects, reducing oxidative stress and weakening the pro-
inflammatory response, as well as promoting neuroplas-
ticity via increased production of BDNF [116]. A pilot,
open-label trial involving adult outpatients with MDD
(n = 23) with comorbid abdominal obesity (waist circum-
ference >35 inches in women and >40 inches in men) or
metabolic syndrome documented that adjunctive pioglit-
azone significantly improves depressive severity (assessed
by the Inventory of Depressive Symptomatology), with a
concurrent reduction in insulin resistance and inflam-
matory markers, as measured by high-sensitive C-
reactive protein [117]. In accord, a subsequent 6-week
RCT confirmed the antidepressant efficacy of pioglita-
zone in obese patients with concomitant polycystic ovar-
ian syndrome and MDD (n = 50), reporting significant
reductions in HDRS scores [118]. Importantly, the au-
thors of this study underscored that antidepressant
properties appeared to be largely independent of insulin-
sensitizing action and are possibly mediated by anti-
inflammatory and antioxidant actions [118], including
the inhibition of the nuclear factor kappa B (NF-κB)
cascade and cytokine production, as well as quinolinic
acid-induced neurotoxicity [119]. In a 6-week RCT on
individuals with moderate-to-severe MDD (n = 40) with-
out diabetes or metabolic syndrome, adjunctive treat-
ment with pioglitazone was associated with greater
decrements in HDRS compared with a placebo group, in
line with the hypothesis that antidepressant effects are
mediated by anti-inflammatory, anti-excitotoxic, and
neuroprotective properties [120].
Finally, the anti-diabetic drug metformin holds prom-
ise as an agent capable of attenuating and/or reverting
neurotoxic effects mediated by inflammatory mecha-
nisms, metabolic and mitochondrial dysfunction, as well
as increased oxidative stress [121]. Clinical evidence of
beneficial antidepressant and neurocognitive potential
was recently documented in an interventional 24-week
study testing the effects of metformin relative to those of
a placebo in individuals with MDD and comorbid type II
diabetes mellitus (n = 58). The effect of metformin was
superior to that of placebo in improving depressive
symptoms in a sample of depressive patients with type II
diabetes mellitus [122]. In addition, metformin improved
memory performance (assessed by the Wechsler Mem-
ory Scale-Revised), which was significantly related to a
decrease in depressive symptoms [122].
Angiotensin-converting enzyme (ACE) inhibitors
Hypertension is a risk factor for cognitive impairment as
well as for depression. ACE inhibitors have immune-
modulating properties and suppress cytokine production
(e.g. IL-1, TNF-α), likely through interference with NF-κB
activation [123]. Preclinical studies have documented that
ACE inhibitors exert memory-improving effects [124].
Preliminary clinical evidence suggests that chronic therapy
with these agents in individuals with mild-to-moderate
hypertension may improve memory performance, as
assessed by the RAVLT and the Wechsler Memory Scale
[125]. Thus, this evidence provides proof of principle for
direct procognitive effects of ACE inhibitors in humans,
and the design of a specific trial aiming to investigate the
effects of ACE inhibitors for the remediation of cognitive
dysfunction in individuals with MDD is warranted.
S-adenosyl methionine (SAMe)
SAMe is formed from the essential amino acid methionine
and adenosine triphosphate. SAMe is a major methyl
donor required for the synthesis of several neurotransmit-
ters and serves as a precursor molecule to the transsulfura-
tion pathway, which leads to the synthesis of glutathione
[126]. The procognitive potential of SAMe was preliminar-
ily documented in a 6-week RCT on 40 SSRI-resistant out-
patients with MDD [127]. Participants allocated to SAMe
therapy showed significant improvements in recall and
word-finding scores on the self-rated Cognitive and Phys-
ical Symptoms Questionnaire compared with a placebo
group. These promising results deserve replication in an
RCT aiming to investigate the possible direct and objective
cognitive effects of SAMe as a primary outcome in partici-
pants with MDD.
Acetyl-L-carnitine (ALC) and alpha lipoic acid (ALA)
ALC is a natural substance involved in both carbohy-
drate and lipid metabolism and exerts a role in the
amelioration of the insulin-resistant state. The pleio-
tropic actions of ALC include enhanced neuronal metab-
olism in the mitochondria and a counteracting effect
toward glutamate-mediate neurotoxicity and hypothal-
amic–pituitary–adrenocortical axis hyperactivity. Four sep-
arate RCTs suggested the efficacy of ALC over a placebo in
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mitigating depressive symptoms in MDD [128]. ALC’s
beneficial effects on cognition have been documented
in the treatment of mild cognitive impairment and
Alzheimer’s disease, as well as of hepatic encephalop-
athy [129, 130]. Taken together, these results provide
the rationale for investigating ALC’s efficacy in the
treatment of neurocognitive deficits in the context of
MDD.
ALA is a cofactor in dehydrogenase complexes that ex-
erts regulatory effects on cellular metabolism. It has been
posited that ALA supplementation in MDD would result
in antidepressant effects, possibly via increased insulin
sensitization and a consequent increase in monoamine
synthesis [131]. Moreover, preclinical studies and investi-
gations in individuals affected by Alzheimer’s disease [132]
provided evidence that ALA may promote neurocognitive
enhancement via pleiotropic mechanisms, including anti-
oxidant mitochondrial activity and anti-inflammatory
properties [133], providing a basis for evaluating ALA’s ef-
ficacy in MDD as well.
Omega-3 polyunsaturated fatty acids (n-3 PUFAs)
n-3 PUFA supplementation may be beneficial in the treat-
ment of several psychiatric disorders, including MDD.
Preclinical evidence suggests that a diet enriched in n-3
PUFA (i.e. ethyl-eicosapentaenoic acid) may attenuate IL-
1-induced memory impairment and block IL-1-induced
increases in serum corticosterone concentration [134].
Moreover, n-3 PUFAs reduce the inflammatory response,
limiting the production of pro-inflammatory mediators by
microglial cells following ischemic insults, and enhance
glutathione-related antioxidant pathways [135, 136]. In
middle-aged to elderly healthy individuals (n = 40), n-3
PUFA supplementation (3 mg/day) significantly improved
cognitive performance (i.e. working memory and atten-
tion) compared with that of a placebo group in a 5-week
RCT [137]. In addition, an inverse relationship was ob-
served between cardiometabolic risk factors and cognitive
performance, suggesting that dietary prevention strategies
may delay the onset of metabolic disorders and associated
cognitive decline. Independent clinical trials and meta-
analyses of RCTs have also provided evidence of the
superiority of n-3 PUFAs, namely eicosapentaenoic and
docosahexaenoic acids, over a placebo as augmentation
agents in the treatment of MDD [138]. However, few stud-
ies have investigated the effects of n-3 PUFAs on cogni-
tion, yielding inconclusive results to date. An RCT
evaluating the effect of n-3 PUFA (1.5 g/day) supplemen-
tation on mood and cognition in mildly to moderately de-
pressed patients did not indicate any significant change in
cognitive functions [139]. However, supplementation with
n-3 PUFAs in an RCT was effective in improving aspects
of emotional information processing in individuals recov-
ered from MDD [140]. Additionally, in a separate cross-
sectional investigation on individuals recovered from
MDD (n = 132), plasma concentrations of n-3 PUFAs cor-
related positively with neurocognitive performance [141].
Further investigations are needed to elucidate the effects
of n-3 PUFAs on cognitive performance in MDD.
Melatonin
Melatonin is a hormone secreted by the pineal gland,
which influences the maintenance of circadian rhythms
and affects energy metabolism. The mechanisms through
which melatonin can exert neuroprotective and cognitive-
enhancing effects include anti-inflammatory and antioxi-
dant properties, as well as enhanced neuroplasticity and
neurogenesis [142]. In a 6-week double-blind RCT, the
combination of melatonin and buspirone provided benefi-
cial effects in treating depressive severity in individuals
with MDD [143]. Another RCT investigating 80 individ-
uals with mild-to-moderate Alzheimer’s disease docu-
mented that the administration of adjunctive melatonin
for 6 months was effective in improving cognitive func-
tions and sleep maintenance [144]. Melatonin, as well as
agomelatine, a melatonergic analogue drug acting as an
MT1/MT2 agonist and 5-HT2C antagonist, may hinder cir-
cadian misalignment and sleep disruption, which has been
posited to contribute to increases in depressive symptoms
through their effect on cognitive control [145].
Modafinil
Modafinil is a stimulant-like agent currently approved
by the US Food and Drug Administration as a treatment
for excessive sleepiness in narcolepsy. This drug has a
pleiotropic mechanism of action targeting several neuro-
transmitters, including but not limited to serotonin,
GABA, glutamate, orexin, and histaminergic systems
[146]. Modafinil has only been tested as a procognitive
agent for MDD in a 4-week open-label trial, enrolling 35
patients with MDD with a partial response to an anti-
depressant at a stable dose [147]. After modafinil aug-
mentation, the authors concluded that no adverse effect
on cognition was reported. However, neurocognitive
function was not a primary outcome of this small, un-
controlled trial. A recent systematic review indicates that
modafinil has procognitive effects in healthy, non-sleep-
deprived individuals [148]. Thus, the potential beneficial
effects of modafinil in remediating cognitive dysfunction
in MDD deserve investigation.
Galantamine
Galantamine is a cholinergic agent, a weak acetylcholin-
esterase inhibitor, and a potent nicotinic receptor modu-
lator. Because of its modulatory effects on nicotinic
receptors, it has been proposed that this drug may
modulate other neurotransmitter systems, including
monoamines, glutamate, and GABA [149]. Two double-
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blind, RCTs evaluated the effects of galantamine
augmentation on neurocognitive function in MDD
[150, 151], and both failed to demonstrate beneficial
effects on cognition. However, they both enrolled
small samples, with that by Holtzheimer et al. [150]
enrolling only elderly participants.
Scopolamine
Several lines of evidence indicate that supersensitivity
of the muscarinic cholinergic system is implicated in
the pathophysiology of MDD [152]. Scopolamine, a po-
tent muscarinic antagonist, promotes a rapid and en-
during antidepressant effect [153]. In addition to its
anticholinergic effect, scopolamine may modulate sero-
tonin, neuropeptide Y, and the dopaminergic and gluta-
matergic systems. Notwithstanding a preclinical and
pharmacological rationale for scopolamine possibly offer-
ing procognitive benefits for MDD, results obtained from
a small proof-of-concept study failed to provide a sign of
efficacy in the cognitive domain (selective attention) [154].
N-acetylcysteine (NAC)
NAC is a potentially useful agent for treating a range of
psychiatric disorders [155]. NAC acts as a modulator of
synaptic glutamate through the cysteine-glutamate ex-
changer, increases glutathione and oxidative defenses,
enhances neurogenesis and mitochondrial function, de-
creases pro-inflammatory cytokines, and regulates apop-
tosis [156]. Cognitive studies of NAC have produced
inconsistent results, which may be linked to variations in
study design [155]. NAC augmentation of standard treat-
ment in Alzheimer’s disease was associated with improve-
ments in verbal abilities and executive control cognitive
tasks compared with controls [157]. NAC administration
after blast traumatic brain injury was associated with im-
proved executive function compared with that observed
for controls [158]. However, NAC pretreatment in healthy
subjects with ketamine-induced psychosis did not reduce
the effect of ketamine on cognition [159]. In a sample with
bipolar disorder, there were no differences between NAC
and placebo with respect to cognitive measures [160]. Fur-
ther, a pooled analysis of participants in two trials of NAC
for schizophrenia and bipolar disorder showed better
working memory performance in the NAC- compared to
the placebo-treated arm (Rapado-Castro M, personal
communication). Definitive studies are warranted.
Curcumin
Preliminary evidence indicates that add-on treatment with
curcumin may promote antidepressant effects in patients
with MDD [161, 162]. Evidence also shows that curcumin
may improve neurocognitive function. For example, in ani-
mal models, administration of curcumin improves chronic,
stress-induced, depressive-like behaviors and cognitive
defects (e.g. impaired learning and memory) [163]. An
RCT examined the acute and chronic effects of curcumin
(400 mg/day) on mood and cognitive functions in elderly
adults [164]. Acute curcumin administration improved
performance on tasks that measured sustained attention
and working memory, whereas chronic treatment also im-
proved mood and fatigue [164]. Curcumin is a pleiotropic
agent that targets immune-inflammatory and oxidative and
nitrosative stress pathways and promotes neuroprotection
and improved neurogenesis [165, 166].
Statins
Statins have been widely prescribed to lower blood choles-
terol and for the prevention of cardiovascular illnesses.
Preclinical studies indicate that simvastatin may have
anxiolytic and antidepressant-like effects in stress-related
murine models [167, 168]. Atorvastatin also promotes
antidepressant-like effects and increases hippocampal
BDNF levels in rodents [169]. In addition, meta-analytic
evidence suggests that statins induce mood-enhancing ef-
fects and decrease the risk of development of de novo de-
pression in humans [170, 171]. Recently, some RCTs have
tested the efficacy of statins for the treatment of depres-
sion. Ghanizadeh and Hedayati [172] randomly allocated
68 participants with MDD to receive either fluoxetine plus
placebo or fluoxetine plus lovastatin from the inception of
treatment. By the end of this trial, the group allocated to
lovastatin augmentation showed a significant reduction in
HDRS scores compared with those measured for a pla-
cebo group. Another 12-week RCT allocated participants
with severe MDD (under standard treatment with citalo-
pram 40 mg/day; n = 60) to receive either adjunctive ator-
vastatin or a placebo [173]. The group allocated to
atorvastatin showed lower HDRS scores by the end of the
trial; however, no participant achieved remission. A subse-
quent 6-week RCT allocated participants meeting criteria
for MDD (n = 48) either to fluoxetine plus placebo or to
fluoxetine plus simvastatin [174]; at study completion, the
latter showed significantly lower depressive symptoms,
whereas differences in remission rates did not achieve
statistical significance.
Statins may have pleiotropic actions in the central ner-
vous system. For example, simvastatin and atorvastatin in-
hibit inflammation by decreasing TNF-α and IL-1β levels.
Simvastatin was also shown to be neuroprotective in an
animal model of ischemia; this effect was associated with
an increase in the activity of endothelial nitric oxide syn-
thase. Furthermore, statins may decrease the activity of
the enzyme indoleamine 2,3-dioxygenase [175], which is
induced by IFN-γ, leading to the cleavage of the essential
amino acid tryptophan, a precursor of serotonin and
melatonin, as well as the production of neurotoxic trypto-
phan catabolites [176]. These multiple actions indicate
that statins may show promise as procognitive agents for
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individuals with MDD. However, no trial to date has eval-
uated the effects of statin members as cognitive enhancers
for patients with MDD.
Coenzyme Q10 (CoQ10)
CoQ10, also referred to as ubiquinone, is found in all
cell types. CoQ10 is a redox modulator, a membrane
stabilizer, and a pivotal cofactor of the mitochondrial
electron transport chain. As an antioxidant, CoQ10 pro-
tects cells from the damaging effects of reactive oxygen
species and reactive nitrogen species [177]. CoQ10 also
has anti-inflammatory effects via the suppression of the
activation of NF-κB and through the modulation of the
transcription of genes governing pro-inflammatory JAK/
STAT pathways [178]. Furthermore, CoQ10 offers neu-
roprotection in animal models of neurodegenerative dis-
eases (e.g. Parkinson’s) [179, 180].
CoQ10 has been implicated in the pathophysiology of
neuro-immune diseases, including MDD [177]. For ex-
ample, decreased peripheral levels of CoQ10 have been re-
ported in patients with MDD relative to those measured
for controls [177]. CoQ10 displays antidepressant-like
effects in chronically stressed rats, with a reduction in hip-
pocampal oxidative/nitrosative DNA damage [181]. These
pleiotropic effects indicate that CoQ10 may hold promise
as a cognitive enhancer for neuro-immune diseases in
which mitochondrial dysfunction is a pathophysiological
hallmark, including but not limited to MDD [182].
Methodological considerations in cognition trials
The results of the above-reviewed studies of novel candi-
date treatments for cognitive dysfunction in MDD re-
main preliminary. The few positive results deserve
replication in well-designed RCTs involving cognitive
dysfunction as a primary outcome in participants with
MDD. One key issue is the lack of consensus on whether
and how to screen for cognitive dysfunction in these tri-
als. For example, the allocation of ‘cognitively intact’ pa-
tients who show no measurable neuropsychological
deficits despite their depression-associated subjective
cognitive complaints [31, 32], which may introduce ceil-
ing effects, remains problematic. Indeed, in a recent
study, we demonstrated that patients with cognitive im-
pairment at baseline had substantially greater chances of
achieving a clinically meaningful cognitive improvement
in response to EPO treatment compared with patients
with normal baseline cognition (Miskowiak et al., un-
published observations). This finding suggests that ob-
jective screening for cognitive impairment should be
performed in future cognition trials. Another issue is the
lack of guidelines on which cognition measures should
be implemented as primary outcomes in these trials (i.e.
single neuropsychological test measures or composite
scores of tests assessing several cognitive domains).
Other unresolved issue is whether patients should be in
remission or can have current mood symptoms at the
time of enrollment. In addition, the allowance of concomi-
tant medications with direct effects on cognition (e.g. ben-
zodiazepines) deserve careful consideration. Moreover, the
use of proper statistical methods that aid in the discrimin-
ation of direct procognitive effects versus beneficial effects
on cognition that occur as a result of mood improve-
ment should also be considered (e.g. path analyses).
The lack of consensus regarding these methodological
issues is a substantial limitation that must be ad-
dressed to advance the field.
Summary
This review provides a comprehensive evaluation of ap-
proved antidepressants and novel therapeutic targets for
cognitive dysfunction in major depressive disorder. Al-
though inconsistent but positive effects of conventional
treatments on cognitive impairment are observed, there
is an absence of compelling evidence of a specific and
direct effect with most antidepressants. Among agents
within a class of antidepressants, it is also uncertain
whether efficacy can be generalized to all members. Fur-
thermore, a major limitation of available evidence is that
cognitive improvement was not a primary outcome in
most trials. Nevertheless, no single antidepressant agent
has received approval by the US Food and Drug Admin-
istration for the treatment of cognitive disturbances as-
sociated with MDD [72]. A shift towards cognitive
function as a priority therapeutic target is occurring in
psychiatry across the developmental trajectory [85, 183].
Advances in cognitive neuroscience are providing insight
into the neurobiology subserving this domain; it is
hoped that the accumulating knowledge might provide
the foundation to develop genuinely novel therapeutic
approaches.
This review covered several novel therapeutic targets
for cognitive impairment in MDD. The data are prelim-
inary across these agents and are promising for EPO,
SAMe, insulin, NAC, and antidiabetic agents. Several
mechanisms may contribute to cognitive dysfunction in
MDD, including but not limited to an over-activation of
the hypothalamic–pituitary–adrenal axis, oxidative and
nitrosative stress, imbalances in pathways involved in
cell survival and death, and immune activation [11].
These pathways may offer a foundation for the develop-
ment of novel drugs and/or the repurposing of existing
agents (e.g. minocycline) for the treatment of cognitive
impairment in depression [99]. Furthermore, in light of
evidence suggesting that the neurobiological underpin-
nings of cognitive functions share both overlapping and
discrete features with those subserving mood regulation,
translational avenues of research are broadening the
range of possible pharmacological novel targets relevant
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to cognitive dysfunction in MDD, including mem-
brane receptors (e.g. metabotropic glutamate receptor
2/3 antagonists) and intracellular pathways, such as
protein kinases, phosphodiesterases, and epigenetic
modifications [85, 184].
Although not the primary focus of this review, various
non-pharmacological treatments that are under active
investigation for their putative cognitive-enhancing ef-
fects are worth mentioning. For example, non-invasive
brain stimulation techniques, namely transcranial mag-
netic stimulation [185] and transcranial direct current
stimulation [186, 187], are promising techniques under
investigation for both their antidepressant and cognitive-
enhancing potential in MDD [188]. Other avenues of re-
search indicate that psychological interventions might
both directly and indirectly ameliorate cognitive per-
formance in individuals with MDD. For example, data
from studies evaluating the impact of cognitive remedi-
ation therapy on cognitive performance in MDD indicate
a positive effect on neuropsychological tasks of atten-
tion, verbal learning and memory, psychomotor speed,
and executive function [189, 190]. However, the evidence
base for psychological treatments for cognitive dysfunc-
tion in MDD also remains rather limited [191]. It ap-
pears possible that an integrated approach including
pharmacological and non-pharmacological treatments
could lead to better effects on cognitive dysfunction in
MDD.
In conclusion, the achievement of ‘cognitive remission’
remains a distinctive unmet need in the treatment of
MDD. Future large-scale controlled trials involving the
cognitive symptoms of depression as primary outcomes
hold promise and may ultimately change the landscape of
care. Furthermore, cognitive deficits should be assessed
objectively (i.e. through neuropsychological batteries) and
through self-reported measures simultaneously. Several
promising novel targets merit investigation as cognitive
enhancers for MDD.
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PUFA: Omega-3 polyunsaturated fatty acid; NAC: N-Acetylcysteine; NF-
κB: Nuclear factor kappa B; RAVLT: Rey Auditory Verbal Learning Test;
RCT: Randomized controlled trial; SAMe: S-Adenosyl methionine;
SNRI: Serotonergic-noradrenergic reuptake inhibitor; SSRI: Selective serotonin
reuptake inhibitor; TCA: Tricyclic antidepressant.
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